Cargando…

Profile of extended-release oxycodone/acetaminophen for acute pain

This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/ac...

Descripción completa

Detalles Bibliográficos
Autor principal: Bekhit, Mary Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621217/
https://www.ncbi.nlm.nih.gov/pubmed/26527898
http://dx.doi.org/10.2147/JPR.S73567
_version_ 1782397404062941184
author Bekhit, Mary Hanna
author_facet Bekhit, Mary Hanna
author_sort Bekhit, Mary Hanna
collection PubMed
description This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/acetaminophen, competes with current US Food and Drug Administration (FDA)-approved opioid formulations available on the market in that it offers two benefits concurrently: a prolonged duration of action, and multimodal analgesia through a combination of an opioid (oxycodone) with a nonopioid component. Current FDA-approved combination analgesics, such as Percocet (oxycodone/acetaminophen), are available solely in immediate-release (IR) formulations.
format Online
Article
Text
id pubmed-4621217
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46212172015-11-02 Profile of extended-release oxycodone/acetaminophen for acute pain Bekhit, Mary Hanna J Pain Res Review This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/acetaminophen, competes with current US Food and Drug Administration (FDA)-approved opioid formulations available on the market in that it offers two benefits concurrently: a prolonged duration of action, and multimodal analgesia through a combination of an opioid (oxycodone) with a nonopioid component. Current FDA-approved combination analgesics, such as Percocet (oxycodone/acetaminophen), are available solely in immediate-release (IR) formulations. Dove Medical Press 2015-10-21 /pmc/articles/PMC4621217/ /pubmed/26527898 http://dx.doi.org/10.2147/JPR.S73567 Text en © 2015 Bekhit. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Bekhit, Mary Hanna
Profile of extended-release oxycodone/acetaminophen for acute pain
title Profile of extended-release oxycodone/acetaminophen for acute pain
title_full Profile of extended-release oxycodone/acetaminophen for acute pain
title_fullStr Profile of extended-release oxycodone/acetaminophen for acute pain
title_full_unstemmed Profile of extended-release oxycodone/acetaminophen for acute pain
title_short Profile of extended-release oxycodone/acetaminophen for acute pain
title_sort profile of extended-release oxycodone/acetaminophen for acute pain
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621217/
https://www.ncbi.nlm.nih.gov/pubmed/26527898
http://dx.doi.org/10.2147/JPR.S73567
work_keys_str_mv AT bekhitmaryhanna profileofextendedreleaseoxycodoneacetaminophenforacutepain